Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF50 in advanced solid tumors
NCT06822998Phase 1Recruiting
- Sponsor
- HighField Biopharmaceuticals
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Small Molecules, Targeted Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of HF50 in solid tumor (advanced stage) (4 arms), sponsored by HighField Biopharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events and 6 more. Started Jun 2025; status: recruiting.
02
Drugs
HF50
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06822998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822998.